Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma

被引：3

作者：

Mai, Elias K. ^{[1
]}

Hielscher, Thomas ^{[2
]}

Bertsch, Uta ^{[1
]}

Schlenzka, Jana ^{[1
]}

Salwender, Hans J. ^{[3
]}

Munder, Markus ^{[4
]}

Gerecke, Christian ^{[5
]}

Duehrsen, Ulrich ^{[6
]}

Brossart, Peter ^{[7
]}

Neben, Kai ^{[8
]}

Hillengass, Jens ^{[1
]}

Raab, Marc S. ^{[1
]}

Merz, Maximilian ^{[1
]}

Baertsch, Marc-Andrea ^{[1
]}

Jauch, Anna ^{[9
]}

Hose, Dirk ^{[1
]}

Martin, Hans ^{[10
]}

Lindemann, Hans-Walter ^{[11
]}

Blau, Igor W. ^{[12
]}

Scheid, Christof ^{[13
]}

Weisel, Katja C. ^{[14
]}

Goldschmidt, Hartmut ^{[1
,15
]}

机构：

[1] Univ Clin Heidelberg, Dept Internal Med 5, Heidelberg, Germany

[2] German Canc Res Ctr, Div Biostat, Heidelberg, Germany

[3] Asklepios Hosp Hamburg Altona, Dept Hematol & Oncol, Hamburg, Germany

[4] Univ Med Ctr Mainz, Dept Internal Med 3, Mainz, Germany

[5] Helios Hosp Berlin Buch, Dept Hematol & Oncol, Berlin, Germany

[6] Univ Clin Essen, Dept Hematol, Essen, Germany

[7] Univ Hosp Bonn, Bonn, Germany

[8] Klinikum Baden Baden, Dept Hematol & Oncol, Baden Baden, Germany

[9] Heidelberg Univ, Inst Human Genet, Heidelberg, Germany

[10] Goethe Univ Frankfurt, Dept Med Hematol Oncol, Frankfurt, Germany

[11] Katholisches Krankenhaus Hagen, Dept Hematol & Oncol, Hagen, Germany

[12] Charite Univ Med Berlin, Med Clin, Berlin, Germany

[13] Univ Hosp Koln, Dept Internal Med 1, Cologne, Germany

[14] Univ Hosp Tubingen, Dept Hematol Oncol & Immunol, Tubingen, Germany

[15] Natl Ctr Tumorerkrankungen NCT Heidelberg, Heidelberg, Germany

来源：

LEUKEMIA | 2019年 / 33卷 / 01期

关键词：

D O I：

10.1038/s41375-018-0195-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：258 / 261

页数：4

共 50 条

[31] Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
Callander, Natalie S.
Silbermann, Rebecca
Kaufman, Jonathan L.
Godby, Kelly N.
Laubach, Jacob
Schmidt, Timothy M.
Sborov, Douglas W.
Medvedova, Eva
Reeves, Brandi
Dhakal, Binod
Rodriguez, Cesar
Chhabra, Saurabh
Chari, Ajai
Bal, Susan
Anderson, Larry D.
Dholaria, Bhagirathbhai R.
Nathwani, Nitya
Hari, Parameswaran
Shah, Nina
Bumma, Naresh
Holstein, Sarah A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Lin, Thomas S.
Giri, Smith
Costa, Luciano J.
Usmani, Saad Z.
Richardson, Paul G.
Voorhees, Peter M.
BLOOD CANCER JOURNAL, 2024, 14 (01)
[32] Response and survival outcomes of daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD) induction in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients
Joseph, Nisha
Kaufman, Jonathan
Lonial, Sagar
Hofmeister, Craig
Dhodapkar, Madhav
Gupta, Vikas
DiCamillo, Sara
Roberts, Danielle
Boise, Lawrence
Nooka, Ajay
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S113 - S113
[33] Carfilzomib Combined with Thalidomide and Low-Dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma: The Carthadex Trial
Wester, Ruth
van der Holt, Bronno
Asselbergs, Emelie
Zweegman, Sonja
Kersten, Marie Jose
Vellenga, Edo
Kooij, Marinus van Marwijk
de Weerdt, Okke
Minnema, Monique C.
Lonergan, Sarah
Palumbo, Antonio
Lokhorst, Henk M.
Broyl, Annemiek
Iskander, Karim Saad
Sonneveld, Pieter
BLOOD, 2017, 130
[34] Correction to: Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma
Yvette N. Lamb
Drugs, 2021, 81 : 183 - 183
[35] Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) Compared to Bortezomib-Dexamethasone (Vel-Dex) As Induction Therapy for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma
Lavoie-Gagnon, Claudie
St-Gelais, Jonathan
Adam, Jean-Philippe
Viens, Daniel
Gagne, Felixe
Decarie, Yann
Lemieux-Blanchard, Emilie
BLOOD, 2017, 130
[36] Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma
Brioli, Annamaria
Zannetti, Beatrice Anna
Zamagni, Elena
Tacchetti, Paola
Pantani, Lucia
Mancuso, Katia
Pezzi, Annalisa
Rocchi, Serena
Cavo, Michele
HAEMATOLOGICA, 2014, 99 (11)
[37] Response adaptive salvage treatment with daratumumab-lenalidomide-dexamethasone for newly diagnosed transplant-eligible multiple myeloma patients failing front-line bortezomib-based induction therapy-ALLG MM21
Lim, S.
Reynolds, J.
Quach, H.
Hutchinson, A.
Kerridge, I.
Janowski, W.
Bergin, K.
Spencer, A.
BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (03) : 900 - 914
[38] Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial
Goldschmidt, Hartmut
Mai, Elias K.
Nievergall, Eva
Fenk, Roland
Bertsch, Uta
Tichy, Diana
Besemer, Britta
Duerig, Jan
Schroers, Roland
Metzler, Ivana V.
Haenel, Mathias
Mann, Christoph
Asemissen, Anne-Marie
Heilmeier, Bernhard
Huhn, Stefanie
Kriegsmann, Katharina
Weinhold, Niels
Luntz, Steffen P.
Holderried, Tobias A. W.
Trautmann-Grill, Karolin
Gezer, Deniz
Klaiber-Hakimi, Maika
Mueller, Martin
Khandanpour, Cyrus
Knauf, Wolfgang
Munder, Markus
Geer, Thomas
Riesenberg, Hendrik
Thomalla, Joerg
Hoffmann, Martin
Raab, Marc-Steffen
Salwender, Hans
Weisel, Katja
BLOOD, 2021, 138
[39] Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial
Wester, Ruth
van der Holt, Bronno
Asselbergs, Emelie
van Duin, Mark
Zweegman, Sonja
Kersten, Marie Jose
Vellenga, Edo
Kooy, Marinus van Marwijk
de Weerdt, Okke
Minnema, Monique
Lonergan, Sarah
Palumbo, Antonio
Lokhorst, Henk M.
Broijl, Annemiek
Sonneveld, Pieter
BLOOD, 2016, 128 (22)
[40] Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial
Wester, Ruth
van der Holt, Bronno
Asselbergs, Emelie
Zweegman, Sonja
Kersten, Marie Jose
Vellenga, Edo
Kooy, Marinus van Marwijk
de Weerdt, Okke
Minnema, Monique
Lonergan, Sarah
Palumbo, Antonio
Lokhorst, Henk
Broijl, Annemiek
Sonneveld, Pieter
HAEMATOLOGICA, 2019, 104 (11) : 2265 - 2273

← 1 2 3 4 5 →